К ВОПРОСУ О ТРАНСПЛАНТАЦИИ ПЕЧЕНИ У БОЛЬНЫХ ГЕПАТОЦЕЛЛЮЛЯРНОЙ КАРЦИНОМОЙ (КРАТКИЙ ОБЗОР ЛИТЕРАТУРЫ)
Аннотация
Гепатоцеллюлярная карцинома (ГЦК) – одна из наиболее распространенных опухолей, занимающая лидирующие позиции в структуре летальности от онкологического заболевания. Первичный рак печени устойчиво ассоциируется с наличием хронического диффузного заболевания печени – вирусного гепатита и цирроза. Ортотопическая трансплантация печени – альтернативный и, возможно – оптимальный метод лечения ГЦК, так как в результате операции полностью удаляется пораженный орган и предраковое заболевание. Отдаленные результаты ОТП зависят от стадии опухолевого поражения, инвазии опухоли в сосуды печени. Золотым стандартом в определении показаний к ОТП при ГЦК принято считать «Миланские критерии» и «Барселонскую» классификацию, обеспечивающие прекрасные отдаленные результаты. Вместе с тем, многими авторами данные критерии признаются излишне строгими, необоснованно лишающими значительную часть больных перспективы трансплантации печени.
Об авторах
М. С. НоврузбековРоссия
Новрузбеков Мурад Сафтарович – кандидат медицинских наук, заведующий научным отделом трансплантации печени
О. Д. Олисов
Россия
Олисов Олег Даниелович – кандидат медицинских наук, старший научный сотрудник отдела трансплантации печени
Список литературы
1. Khan A.S, et al. Current surgical treatment strategies for hepatocellular carcinoma in North America. //World J Gastroenterol 2014; 20(41): 15007–15017.
2. Bruix J., Sherman M. Management of Hepatocellular Carcinoma: An update (AASLD practice guideline) // Hepatology. July 2010.
3. Byam J, et al. Liver transplantation for hepatocellular carcinoma. // Hepatobiliary Surg Nutr 2013;2(1):22–30.
4. Elshamy M, et al. Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria // World J Hepatol 2016 July 28; 8(21): 874–880.
5. Mazzaferro V., et al. Liver transplantation for hepatocellular carcinoma. // Annals of Surgical Oncology 15(4):1001–1007.
6. Weledji E., et al. How grim is hepatocellular carcinoma? // Annals of Medicine and Surgery 3 (2014) 71–76.
7. Hackl C., et al. Liver transplantation for malignancy: current treatment strategies and future perspectives. // World J Gastroenterol 2014 May 14; 20(18): 5331–5344.
8. Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. // ISRN Hepatology, Vol. 2014 (2014), Article ID706945, 25 pages.
9. Mazzaferro V, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. // N Engl J Med 1996; 334:693–699.
10. Clavien et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. // Lancet Oncol. 2012 Jan; 13(1): e11–e22.
11. Mehta N, et al. Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list. // Liver Transpl. 2014; 20(5): 627–628.
12. Graziadei IW, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. // Liver Transpl 9(6):557–63, Jun 2003.
13. Llovet JM, et al. Prognosis of hepatocellular carcinoma: the BCLC staging classification. // Semin Liver Dis. 1999;19:329–338.
14. Yao FY, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. // Hepatology 2001; 33: 1394–1403.
15. Herrero JI, et al. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. // Liver Transpl 2001; 7: 631–636.
16. Roayaie S, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. // Ann Surg 2002; 235: 533–539.
17. Kneteman NM, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. // Liver Transpl 2004; 10: 1301–131.
18. Onaca N, et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. // Liver Transpl 2007; 13: 391–399.
19. Soejima Y, et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. // Transplantation 2007; 83: 893–899.
20. Jonas S, et al. Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center. // Liver Transpl 2007; 13: 896–903.
21. Sugawara Y, et al. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. // Dig Dis 2007; 25: 310–312.
22. Silva M, et al. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. // Liver Transpl 2008; 14: 1449–1460.
23. Mazzaferro V, et al; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. // Lancet Oncol. 2009; 10: 35–43.
24. Kwon CH, et al. HCC in living donor liver transplantation: can we expand the Milan criteria? // Dig Dis 2007; 25: 313–319.
25. Takada Y, et al. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. // Dig Dis 2007; 25: 299–302.
26. Zheng SS, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. // Transplantation 2008; 85: 1726–1732.
27. Fujiki M, et al. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. // Am J Transplant 2009; 9: 2362–2371.
28. Lai Q, et al. Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation. // Clin Transplant 2012; 26: E125-E131.
29. Grąt M, et al. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. //World J Surg 2014; 38: 2698–2707.
30. Toso C, et al. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. // Hepatology 2015; 62: 158–165.
31. Lee SD, et al. Clinical impact of 18F-Fluorodeoxyglucose positron emission tomography /computed tomography in living donor liver transplantation for advanced hepatocellular carcinoma. // Transplantation 2015; 99: 2142–2149.
32. See C. C., Sheung T. F. Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation. // Hepatobiliary Surg Nutr 2013;2(2):84–88.
33. Duffy J. P., et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. // Ann Surg 2007;246: 502–511.
34. Xu D. W., et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review. // World J Gastroenterol 2016; 22(12): 3325–3334.
35. Mazzaferro V., et al. Liver transplantation for hepatocellular carcinoma. // Annals of Surgical Oncology 15(4):1001–1007.
36. Chapman WC, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. // Ann Surg 2008; 248: 617–625.
37. Yao FY, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. // Hepatology 2008; 48: 819–827.
38. Vagefi PA, Hirose R. Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant Sorafenib in locoregional therapy? // J Gastrointest Canc (2010) 41:217–220.
39. Yoo EJ, et al. Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. OncoTargets and Therapy 2013:6 755–759.
40. Bhardwaj N., et al. Current treatment approaches to HCC with a special consideration to transplantation. // Journal of Transplantation Volume 2016, Article ID7926264, 9 pages.
Рецензия
Для цитирования:
Новрузбеков М.С., Олисов О.Д. К ВОПРОСУ О ТРАНСПЛАНТАЦИИ ПЕЧЕНИ У БОЛЬНЫХ ГЕПАТОЦЕЛЛЮЛЯРНОЙ КАРЦИНОМОЙ (КРАТКИЙ ОБЗОР ЛИТЕРАТУРЫ). Злокачественные опухоли. 2016;(4s1):36-39.